Investors / United States / F-Prime Capital
F-Prime Capital
Venture capital · Cambridge, MA, United States · North America
F-Prime Capital is a venture capital firm that backs companies in life sciences, technology, healthtech and services, and crypto. It reports over $5.3 billion in assets under management and a global portfolio of more than 400 companies across the Americas, Europe and Asia.
Invests inHealthcare & BiotechFintech
In its own wordslife scienceshealthcareenterprise softwarefintechcryptofrontier tech
Your fit with F-Prime Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsF-Prime Capital lists 273 checked portfolio companies on its own site and is named in 43 funding rounds, 11 of them as lead. Its most frequent entry is Series A, 49% of the companies with a known first round. Its largest themes are Healthcare & Biotech (42%), Fintech (20%) and AI & Machine Learning (10%). 66% of its companies are based in United States. It invests most often alongside Y Combinator, ARCH Venture Partners and NEA.
Counts come from funding rounds that name F-Prime Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not F-Prime Capital's whole history. Rounds on record name 42 companies; its own site lists 273. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundF-Prime Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 10% |
| Series A | 49% |
| Series B | 29% |
| Growth | 12% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 1 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 16 | 3 |
| '26 | 24 | 8 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 99th | 273 companies |
| Recent activity | 99th | 26 rounds in 12 months |
| Early stage | 55th | 10% of entries at pre-seed or seed |
| Evidence | 83th | 13% of companies confirmed by a round |
| Sector focus | 76th | 42% in its largest sector |
| Reach | 99th | 22 countries |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 42% | 15% |
| Fintech | 20% | 12% |
| AI & Machine Learning | 10% | 18% |
| Crypto & Web3 | 6% | 1% |
| E-commerce & Marketplaces | 3% | 6% |
| Legal & Compliance | 3% | 2% |
| Enterprise Software | 2% | 8% |
| Cybersecurity | 2% | 4% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Y Combinator | 21 |
| ARCH Venture Partners | 15 |
| NEA | 11 |
| Andreessen Horowitz | 9 |
| Eight Roads | 9 |
| Foresite Capital | 9 |
| General Catalyst | 9 |
| Lightspeed Venture Partners | 9 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers26497%
- No longer answers00%
- Points to another company93%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherCompare F-Prime Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with F-Prime Capital| Date | Company | Stage |
|---|---|---|
| 10 Nov 2026 | Series B | |
| 5 Nov 2026 | Series B | |
| 20 Oct 2026 | Series A Led | |
| 6 Oct 2026 | Series A Led | |
| 5 Oct 2026 | Series C+ | |
| 20 Aug 2026 | Seed | |
| 11 Aug 2026 | Series A | |
| 27 Jul 2026 | Series A Led |
Round details for F-Prime Capital
Amounts, full round histories and every co-investor in F-Prime Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
273 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 1Money Network is building a vertically integrated operating system for stablecoin payments | Fintech | Portfolio page | ||
| 1upHealth provides health data and interoperability solutions | Healthcare & Biotech | Portfolio page | ||
| The company provides a platform for leveraging real-world assets onchain and earning yield by lending against them. | Fintech | Portfolio page | ||
| The company develops digital therapeutics for cognitive impairment | Healthcare & Biotech | Portfolio page | ||
| ABK Biomedical develops and commercializes medical device technologies to treat cancer | Healthcare & Biotech | Oct 2025Series C+ | Page + round | |
| AblePay makes paying out-of-pocket medical expenses easy and convenient for patients | Healthcare & Biotech | Portfolio page | ||
| Acacia Pharma is a commercial stage biopharmaceutical group focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy. | Healthcare & Biotech | Portfolio page | ||
| Aclaris Therapeutics is a biopharmaceutical company that strives to translate scientific discovery into everyday victories in immuno-inflammatory conditions. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Adaptimmune is involved in cell therapies against cancer. | Healthcare & Biotech | Portfolio page | ||
| Adcentrx Therapeutics is a clinical-stage biotechnology company focused on accelerating breakthroughs in developing protein conjugate therapeutics for cancer and other life-threatening diseases. | Healthcare & Biotech | Portfolio page | ||
| Adela delivers highly sensitive, blood-based tests that uncover critical insights from cell-free DNA for cancer detection and monitoring | Healthcare & Biotech | Portfolio page | ||
| Aera Therapeutics develops delivery platforms for genetic medicines | Healthcare & Biotech | Portfolio page | ||
| Affinia Therapeutics develops gene therapies, specifically adeno-associated virus (AAV) gene therapy, for diseases such as BAG3-associated dilated cardiomyopathy | Healthcare & Biotech | Oct 2025Series C+ | Page + round | |
| Alfred Pay provides stablecoin payment infrastructure for Latin America, allowing businesses to move money across the region in seconds | FintechCrypto & Web3 | Jan 2026Series A | Page + round | |
| Almanac Health provides an AI assistant for clinicians to help with clinical decisions and workflows. | Healthcare & Biotech | Portfolio page | ||
| Almanac Health backs and builds healthcare businesses in partnership with exceptional people. | Healthcare & Biotech | Apr 2026Seed | Funding round | |
| Amber Therapeutics is developing the first adaptive neuromodulation therapy to treat women suffering with mixed urinary incontinence | Healthcare & Biotech | Portfolio page | ||
| AmplifyMD provides a virtual care platform for hospitals and health systems to deliver high-quality care remotely | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| AppliedVR combines immersive technology with therapeutic techniques to create healthcare solutions. | Healthcare & BiotechMedia & Entertainment | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- fprimecapital.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 22 Dec 2016
- Companies checked
- 273
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get F-Prime Capital's profile as data
Pull F-Prime Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/fprimecapital.com
# also
GET /v1/firms/fprimecapital.com/portfolio
GET /v1/firms/fprimecapital.com/coinvestors
GET /v1/firms/fprimecapital.com/news